Immusoft

Thank you, Alex Philippidis and Genetic Engineering & Biotechnology News, for this insightful, in-depth, exciting story! https://lnkd.in/eJq4vtWq #bcell

Thank you, Lei Lei Wu and Endpoints News, for today's story. We are excited about our Phase 1 results and what lies ahead for MPS 1 patients. #bcell https://lnkd.in/eA4xW5Bk

#ICYMI Our Chairman and CEO, Sean Ainsworth, is presenting at the Cell and Gene Meeting on the Mesa today in Phoenix. Join him in Ballroom G at the Arizona Biltmore at 5:15 PST.  #bcell #CGMesa24

Our Chairman and CEO, Sean Ainsworth, looks forward to connecting with colleagues and friends at the Cell and Gene Meeting on the Mesa.  Immusoft is excited to announce positive phase 1 data for the first engineered B cell therapy in a clinical trial next week. #bcell #CGMesa24

Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial. “Although the Phase 1 focus is safety, we have observed activity and functional improvements, even at the low dose, far beyond our initial expectations, and are very excited by this data,” said Sean Ainsworth, Immusoft CEO. Read Below. Webinar: https://lnkd.in/eB77BxZF Press release: https://lnkd.in/eEijxyka

Our CEO, Sean Ainsworth, looks forward to being the keynote speaker at the Invest360 Investor Showcase on Friday, September 20th, at 12:45. #Immusoft #bcell #raredisease #celltherapy

Our CEO, Sean Ainsworth, and VP of Corporate Development, Alissa R. Kerner, PhD are excited to collaborate and partner at Cantor Fitzgerald's Healthcare Conference in NY this week. #CantorHealthcareConference2024

This is an outstanding piece in Nature Biotechnology on B cells as biofactories - the field that Immusoft pioneered and continues to lead. "The clinical possibilities appear to be vast, given the various shortcomings of classical enzyme replacement therapy, antibody therapy, gene therapy and different forms of cell therapy." They are vast, indeed! It's exciting to be in the clinic and expanding on the immense potential. Thank you Cormac Sheridan - great article.

What if a patient's own immune cells could produce therapeutics 𝘪𝘯𝘴𝘪𝘥𝘦 𝘵𝘩𝘦 𝘣𝘰𝘥𝘺? With promising early insights from the first-ever clinical trial of engineered B cell therapies, we're getting closer to finding out. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🔬 Researchers are creating B cell "biofactories" that express therapeutic proteins within patients' bodies, aiming to develop safe and more efficient treatments. ⚕ Designed to treat a rare fatal genetic condition called MPS I, Immusoft's lead technology has been administered to the first human patient. 💊 Early readouts of the Phase I human clinical trial show excellent safety and pharmacodynamic effects, per Immusoft CEO Sean Ainsworth. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 Springer Nature Group 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐟𝐫𝐨𝐦 Cormac Sheridan: https://lnkd.in/embsZb4V

🔬 Fascinating work with B cells for cell therapy! B cells – which produce antibodies to attack invading bacteria, viruses, and toxins – are a great natural defender in the human body. However, a new Phase 1 trial is reprogramming these B cells to produce other proteins, instead of antibodies, for therapeutic benefit. It is hoped the engineered B cells could give rise to potential treatments for diseases including obesity, diabetes, CNS disorders and cancer. “One of the main benefits of engineered B cells is that, because B cells naturally reside in the bone marrow, they don’t require the preconditioning regimen associated with gene-modified stem cells" - Sean Ainsworth, CEO of Immusoft Engineered B cells are being evaluated in ongoing clinical trials for their efficacy and tolerability. But while their prospects are exciting, safety concerns include genetic mutations that could give rise to cancer. Read more about engineering B cells in Labiotech.eu ⬇️ https://lnkd.in/e34-FWJB #ManufacturingBrighterFutures #CellTherapy #Biotechnology #PatientAccess